In a US retrospective study of data on veterans with compensated cirrhosis, more than half progressed to complications after approximately 5 years.

Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...

The UK Health Security Agency (UKHSA) has announced the launch of a whole genome sequencing service to tackle hepatitis C virus (HCV). The service is aimed at monitoring drug resi ...